Dendritic cell factor 1 inhibits proliferation and migration and induces apoptosis of neuroblastoma cells by inhibiting the ERK signaling pathway

Luo,Guanghong; Feng,Ruili; Sun,Yangyang; Zheng,Lili; Wang,Yajiang; Chen,Yanlu; Wen,Tieqiao

doi:10.3892/or.2018.6796

Dendritic cell factor 1 inhibits proliferation and migration and induces apoptosis of neuroblastoma cells by inhibiting the ERK signaling pathway

Authors:
- Guanghong Luo
- Ruili Feng
- Yangyang Sun
- Lili Zheng
- Yajiang Wang
- Yanlu Chen
- Tieqiao Wen
View Affiliations

Affiliations: Laboratory of Molecular Neural Biology, School of Life Sciences, Shanghai University, Shanghai 200444, P.R. China
Published online on: October 16, 2018 https://doi.org/10.3892/or.2018.6796
Pages: 103-112
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumor that affects mainly children and has extremely high mortality and recurrence rates. A previous study revealed that dendritic cell factor 1 (DCF1), also called transmembrane protein 59, could activate apoptosis in glioma cells. In the present study, we applied immunofluorescence, western blot analysis, flow cytometry and cell tumorigenicity to investigate the DCF1 mechanisms involved in NB apoptosis. DCF1 was overexpressed in Neuro-2a and SK-N-SH cells through instantaneous transfection. The data revealed that overexpression of DCF1 could inhibit cell proliferation, migration, invasion and promote cell apoptosis in vitro, and suppress NB growth in vivo. The ERK1/2 signaling pathway, which promotes cell survival, was the target of DCF1 in neuroblastoma cells. All the results indicated that DCF1 could be a potential therapeutic target for the understanding and treatment of NB.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
3	DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H, et al: Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 21:181–189. 1999. View Article : Google Scholar : PubMed/NCBI
4	Cotterill SJ, Parker L, More L and Craft AW: Neuroblastoma: Changing incidence and survival in young people aged 0–24 years. A report from the North of England Young Persons' Malignant Disease Registry. Med Pediatr Oncol. 36:231–234. 2001. View Article : Google Scholar : PubMed/NCBI
5	Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et al: ; INRG Task Force: The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol. 27:289–297. 2009. View Article : Google Scholar : PubMed/NCBI
6	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yang XH, Tang F, Shin J and Cunningham JM: A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature). Sci Rep. 7:412017. View Article : Google Scholar : PubMed/NCBI
8	DeNardo BD, Holloway MP, Ji Q, Nguyen KT, Cheng Y, Valentine MB, Salomon A and Altura RA: Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One. 8:e825132013. View Article : Google Scholar : PubMed/NCBI
9	Martinez MA, Ubeda A, Cid MA and Trillo MA: The proliferative response of NB69 human neuroblastoma cells to a 50 Hz magnetic field is mediated by ERK1/2 signaling. Cell Physiol Biochem. 29:675–686. 2012. View Article : Google Scholar : PubMed/NCBI
10	Vieira GC, Chockalingam S, Melegh Z, Greenhough A, Malik S, Szemes M, Park JH, Kaidi A, Zhou L, Catchpoole D, et al: LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma. Oncotarget. 6:40053–40067. 2015. View Article : Google Scholar : PubMed/NCBI
11	Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, et al: Mutant NRASQ61 shares signaling similarities across various cancer types-potential implications for future therapies. Oncotarget. 5:7936–7944. 2014. View Article : Google Scholar : PubMed/NCBI
12	Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, et al: The genetic landscape of high-risk neuroblastoma. Nat Genet. 45:279–284. 2013. View Article : Google Scholar : PubMed/NCBI
13	Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, et al: Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 47:864–871. 2015. View Article : Google Scholar : PubMed/NCBI
14	Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, et al: Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 47:872–877. 2015. View Article : Google Scholar : PubMed/NCBI
15	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
16	Montagut C and Settleman J: Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–134. 2009. View Article : Google Scholar : PubMed/NCBI
17	Yu Z, Ye S, Hu G, Lv M, Tu Z, Zhou K and Li Q: The RAF-MEK-ERK pathway: Targeting ERK to overcome obstacles to effective cancer therapy. Future Med Chem. 7:269–289. 2015. View Article : Google Scholar : PubMed/NCBI
18	Wang L, Wang J, Wu Y, Wu J, Pang S, Pan R and Wen T: A novel function of dcf1 during the differentiation of neural stem cells in vitro. Cell Mol Neurobiol. 28:887–894. 2008. View Article : Google Scholar : PubMed/NCBI
19	Li X, Feng R, Huang C, Wang H, Wang J, Zhang Z, Yan H and Wen T: MicroRNA-351 regulates TMEM 59 (DCF1) expression and mediates neural stem cell morphogenesis. RNA Biol. 9:292–301. 2012. View Article : Google Scholar : PubMed/NCBI
20	Xie Y, Li Q, Yang Q, Yang M, Zhang Z, Zhu L, Yan H, Feng R, Zhang S, Huang C, et al: Overexpression of DCF1 inhibits glioma through destruction of mitochondria and activation of apoptosis pathway. Sci Rep. 4:37022014. View Article : Google Scholar : PubMed/NCBI
21	Liu Q, Feng R, Chen Y, Luo G, Yan H, Chen L, Lin R, Ding Y and Wen T: Dcf1 triggers dendritic spine formation and facilitates memory acquisition. Mol Neurobiol. 55:763–775. 2017. View Article : Google Scholar : PubMed/NCBI
22	Liu Q, Chen Y, Li Q, Wu L and Wen T: Dcf1 regulates neuropeptide expression and maintains energy balance. Neurosci Lett. 650:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
23	Xie Y, Li Q, Yang Q, Yang M, Zhang Z, Zhu L, Yan H, Feng R, Zhang S, Huang C, et al: Overexpression of DCF1 inhibits glioma through destruction of mitochondria and activation of apoptosis pathway. Sci Rep. 4:pp. 37022014, https://doi.org/10.1038/srep03702 View Article : Google Scholar : PubMed/NCBI
24	Kim MS, Yu JM, Kim HJ, Kim HB, Kim ST, Jang SK, Choi YW, Lee DI and Joo SS: Ginsenoside Re and Rd enhance the expression of cholinergic markers and neuronal differentiation in Neuro-2a cells. Biol Pharm Bull. 37:826–833. 2014. View Article : Google Scholar : PubMed/NCBI
25	Weibel S, Hofmann E, Basse-Luesebrink TC, Donat U, Seubert C, Adelfinger M, Gnamlin P, Kober C, Frentzen A, Gentschev I, et al: Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer. J Transl Med. 11:1062013.https://doi.org/10.1186/1479-5876-11-106 View Article : Google Scholar : PubMed/NCBI
26	Pagano M, Pepperkok R, Verde F, Ansorge W and Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J. 11:961–971. 1992. View Article : Google Scholar : PubMed/NCBI
27	Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T and Green DR: Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci USA. 105:20327–20332. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
29	Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK and Oh BH: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry. 40:1117–1123. 2001. View Article : Google Scholar : PubMed/NCBI
30	Lavoie JN, L'Allemain G, Brunet A, Müller R and Pouysségur J: Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 271:20608–20616. 1996. View Article : Google Scholar : PubMed/NCBI
31	Caunt CJ, Sale MJ, Smith PD and Cook SJ: ME K1 and MEK2 inhibitors and cancer therapy: The long and winding road. Nat Rev Cancer. 15:577–592. 2015. View Article : Google Scholar : PubMed/NCBI
32	Liu Y, Zhang X, Yang B, Zhuang H, Guo H, Wei W, Li Y, Chen R, Li Y and Zhang N: Demethylation-induced overexpression of Shc3 drives c-Raf-independent activation of MEK/ERK in HCC. Cancer Res. 78:2219–2232. 2018. View Article : Google Scholar : PubMed/NCBI
33	Yang C, Zheng W and Du W: CXCR3A contributes to the invasion and metastasis of gastric cancer cells. Oncol Rep. 36:1686–1692. 2016. View Article : Google Scholar : PubMed/NCBI
34	Hou H, Ge C, Sun H, Li H, Li J and Tian H: Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway. Cancer Sci. 109:1088–1100. 2018. View Article : Google Scholar : PubMed/NCBI
35	Zhao H, Liu B and Li J: LIM and SH3 protein 1 knockdown suppresses proliferation and metastasis of colorectal carcinoma cells via inhibition of the mitogen-activated protein kinase signaling pathway. Oncol Lett. 15:6839–6844. 2018.PubMed/NCBI
36	Ferreira-Silva GA, Lages CC, Sartorelli P, Hasegawa FR, Soares MG and Ionta M: Casearin D inhibits ERK phosphorylation and induces downregulation of cyclin D1 in HepG2 cells. Toxicol In Vitro. 38:27–32. 2017. View Article : Google Scholar : PubMed/NCBI
37	Xu X, Wang Q, He Y, Ding L, Zhong F, Ou Y, Shen Y, Liu H and He S: ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR). Ann Hematol. 96:847–858. 2017. View Article : Google Scholar : PubMed/NCBI
38	Yan Y, Wang L, He J, Liu P, Lv X and Zhang Y, Xu X, Zhang L and Zhang Y: Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. Biomed Pharmacother. 88:395–402. 2017. View Article : Google Scholar : PubMed/NCBI
39	Uehling DE and Harris PA: Recent progress on MAP kinase pathway inhibitors. Bioorg Med Chem Lett. 25:4047–4056. 2015. View Article : Google Scholar : PubMed/NCBI
40	Wu PK and Park JI: MEK1/2 Inhibitors: Molecular activity and resistance mechanisms. Semin Oncol. 42:849–862. 2015. View Article : Google Scholar : PubMed/NCBI
41	Serini S and Calviello G: Modulation of Ras/ERK and phosphoinositide signaling by long-chain n-3 PUFA in breast cancer and their potential complementary role in combination with targeted drugs. Nutrients. 9:1852017.doi:10.3390/nu9030185. View Article : Google Scholar :